Literature DB >> 11390583

Potential sources of the 1995 Venezuelan equine encephalitis subtype IC epidemic.

A C Brault1, A M Powers, G Medina, E Wang, W Kang, R A Salas, J De Siger, S C Weaver.   

Abstract

Venezuelan equine encephalitis viruses (VEEV) belonging to subtype IC have caused three (1962-1964, 1992-1993 and 1995) major equine epizootics and epidemics. Previous sequence analyses of a portion of the envelope glycoprotein gene demonstrated a high degree of conservation among isolates from the 1962-1964 and the 1995 outbreaks, as well as a 1983 interepizootic mosquito isolate from Panaquire, Venezuela. However, unlike subtype IAB VEEV that were used to prepare inactivated vaccines that probably initiated several outbreaks, subtype IC viruses have not been used for vaccine production and their conservation cannot be explained in this way. To characterize further subtype IC VEEV conservation and to evaluate potential sources of the 1995 outbreak, we sequenced the complete genomes of three isolates from the 1962-1964 outbreak, the 1983 Panaquire interepizootic isolate, and two isolates from 1995. The sequence of the Panaquire isolate, and that of virus isolated from a mouse brain antigen prepared from subtype IC strain P676 and used in the same laboratory, suggested that the Panaquire isolate represents a laboratory contaminant. Some authentic epizootic IC strains isolated 32 years apart showed a greater degree of sequence identity than did isolates from the same (1962-1964 or 1995) outbreak. If these viruses were circulating and replicating between 1964 and 1995, their rate of sequence evolution was at least 10-fold lower than that estimated during outbreaks or that of closely related enzootic VEEV strains that circulate continuously. Current understanding of alphavirus evolution is inconsistent with this conservation. This subtype IC VEEV conservation, combined with phylogenetic relationships, suggests the possibility that the 1995 outbreak was initiated by a laboratory strain.

Entities:  

Mesh:

Year:  2001        PMID: 11390583      PMCID: PMC114297          DOI: 10.1128/JVI.75.13.5823-5832.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Search for persistent epizootic Venezuelan encephalitis virus in Guatemala, El Salvador and Nicaragua during 1970-1975.

Authors:  W F Scherer; J V Ordonez; R W Dickerman; J E Navarro
Journal:  Am J Epidemiol       Date:  1976-07       Impact factor: 4.897

2.  Monoclonal antibodies capable of distinguishing epizootic from enzootic varieties of subtype 1 Venezuelan equine encephalitis viruses in a rapid indirect immunofluorescence assay.

Authors:  J T Roehrig; R A Bolin
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

3.  Recovery of Venezuelan equine encephalomyelitis virus in Panama. A fatal case in man.

Authors:  K M Johnson; A Shelokov; P H Peralta; G J Dammin; N A Young
Journal:  Am J Trop Med Hyg       Date:  1968-05       Impact factor: 2.345

4.  Venezuelan equine encephalitis and Oropouche virus infections among Peruvian army troops in the Amazon region of Peru.

Authors:  D M Watts; V Lavera; J Callahan; C Rossi; M S Oberste; J T Roehrig; C B Cropp; N Karabatsos; J F Smith; D J Gubler; M T Wooster; W M Nelson; C G Hayes
Journal:  Am J Trop Med Hyg       Date:  1997-06       Impact factor: 2.345

5.  Genetic diversity and relationships among Venezuelan equine encephalitis virus field isolates from Colombia and Venezuela.

Authors:  A C Moncayo; G M Medina; Z Kalvatchev; A C Brault; R Barrera; J Boshell; C Ferro; J E Freier; J C Navarro; R Salas; J De Siger; C Vasquez; R Walder; S C Weaver
Journal:  Am J Trop Med Hyg       Date:  2001-12       Impact factor: 2.345

6.  Epidemic Venezuelan equine encephalitis in La Guajira, Colombia, 1995.

Authors:  F Rivas; L A Diaz; V M Cardenas; E Daza; L Bruzon; A Alcala; O De la Hoz; F M Caceres; G Aristizabal; J W Martinez; D Revelo; F De la Hoz; J Boshell; T Camacho; L Calderon; V A Olano; L I Villarreal; D Roselli; G Alvarez; G Ludwig; T Tsai
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

Review 7.  The alphaviruses: gene expression, replication, and evolution.

Authors:  J H Strauss; E G Strauss
Journal:  Microbiol Rev       Date:  1994-09

8.  Diversity within natural populations of eastern equine encephalomyelitis virus.

Authors:  S C Weaver; L A Bellew; L Gousset; P M Repik; T W Scott; J J Holland
Journal:  Virology       Date:  1993-08       Impact factor: 3.616

9.  Evolution of alphaviruses in the eastern equine encephalomyelitis complex.

Authors:  S C Weaver; A Hagenbaugh; L A Bellew; L Gousset; V Mallampalli; J J Holland; T W Scott
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

10.  Molecular evidence that epizootic Venezuelan equine encephalitis (VEE) I-AB viruses are not evolutionary derivatives of enzootic VEE subtype I-E or II viruses.

Authors:  J M Sneider; R M Kinney; K R Tsuchiya; D W Trent
Journal:  J Gen Virol       Date:  1993-03       Impact factor: 3.891

View more
  14 in total

1.  Efficient functional pseudotyping of oncoretroviral and lentiviral vectors by Venezuelan equine encephalitis virus envelope proteins.

Authors:  Andrey A Kolokoltsov; Scott C Weaver; Robert A Davey
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Envelope glycoprotein mutations mediate equine amplification and virulence of epizootic venezuelan equine encephalitis virus.

Authors:  Ivorlyne P Greene; Slobodan Paessler; Laura Austgen; Michael Anishchenko; Aaron C Brault; Richard A Bowen; Scott C Weaver
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Positively charged amino acid substitutions in the e2 envelope glycoprotein are associated with the emergence of venezuelan equine encephalitis virus.

Authors:  Aaron C Brault; Ann M Powers; Edward C Holmes; C H Woelk; Scott C Weaver
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

4.  Vector infection determinants of Venezuelan equine encephalitis virus reside within the E2 envelope glycoprotein.

Authors:  Aaron C Brault; Ann M Powers; Scott C Weaver
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

5.  Generation and characterization of closely related epizootic and enzootic infectious cDNA clones for studying interferon sensitivity and emergence mechanisms of Venezuelan equine encephalitis virus.

Authors:  Michael Anishchenko; Slobodan Paessler; Ivorlyne P Greene; Patricia V Aguilar; Anne-Sophie Carrara; Scott C Weaver
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

6.  Isolation and phylogenetic analysis of Mucambo virus (Venezuelan equine encephalitis complex subtype IIIA) in Trinidad.

Authors:  Albert J Auguste; Sara M Volk; Nicole C Arrigo; Raymond Martinez; Vernie Ramkissoon; A Paige Adams; Nadin N Thompson; Abiodun A Adesiyun; Dave D Chadee; Jerome E Foster; Amelia P A Travassos Da Rosa; Robert B Tesh; Scott C Weaver; Christine V F Carrington
Journal:  Virology       Date:  2009-07-25       Impact factor: 3.616

Review 7.  Present and future arboviral threats.

Authors:  Scott C Weaver; William K Reisen
Journal:  Antiviral Res       Date:  2009-10-24       Impact factor: 5.970

8.  Glycosaminoglycan binding properties of natural venezuelan equine encephalitis virus isolates.

Authors:  Eryu Wang; Aaron C Brault; Ann M Powers; Wenli Kang; Scott C Weaver
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

9.  Venezuelan equine encephalitis virus, southern Mexico.

Authors:  José G Estrada-Franco; Roberto Navarro-Lopez; Jerome E Freier; Dionicio Cordova; Tamara Clements; Abelardo Moncayo; Wenli Kang; Carlos Gomez-Hernandez; Gabriela Rodriguez-Dominguez; George V Ludwig; Scott C Weaver
Journal:  Emerg Infect Dis       Date:  2004-12       Impact factor: 6.883

10.  Postepizootic persistence of Venezuelan equine encephalitis virus, Venezuela.

Authors:  Juan-Carlos Navarro; Gladys Medina; Clovis Vasquez; Lark L Coffey; Eryu Wang; Alexander Suárez; Hernán Biord; Marlene Salas; Scott C Weaver
Journal:  Emerg Infect Dis       Date:  2005-12       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.